Teva Pharmaceutical Industries Ltd.

Regulatory Filings • Mar 6, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number:	3235-0104
Estimated average burden
hours per response	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person McAvoy David R.	2. Date of Event Requiring Statement (Month/Day/Year) 03/04/2024	3. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA
Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora Hanevi'a Street		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)	15. If Amendment, Date Original Filed (Month/Day/Year)
(Street) Tel Aviv, L3 6944020		10% Owner Director X Officer (give title below) EVP, Chief Legal Officer	Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person
(City) (Zip) (State)			Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security	2. Amount of Securities	3. Ownership	4. Nature of Indirect Beneficial Ownership
(Instr. 4)	Beneficially Owned	Form: Direct (D) (Instr. 5)
	(Instr. 4)	or Indirect (1)
		(Instr. 5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	12. Date Exercisable			3. Title and Amount of Securities	4. Conversion or 5. Ownership		6. Nature of Indirect Beneficial
(Instr. 4)	and Expiration Date (Month/Day/Year)					Underlying Derivative Security	Exercise Price	Form of	Ownership
			(Instr. 4)		of Derivative	Derivative	(Instr. 5)
					Security	Security: Direct
Date Exercisable Date		Expiration				(D) or Indirect
			Amount or Number of
				I Shares		(Instr. 5)

Explanation of Responses:

Signatures

/s/ Dov Bergwerk as attorney-in-fact for David R. McAvoy 03/05/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 18tf(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Persons who respond to the collection of in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

KNOW ALL BY THESE PRESENTS, that the unders constitutes and appoints Dov Bergwerk, Shire Aran-Porat and Matar Kimchi signing singly, as the undersigned's the and lawful attorney-in-fact, with full power and authority as hereinater described of the undersigned to:

• (1) = prepare, excente, axanowledge, deliver and 5 (including any amendments thereto) with respect to the securities of Teva Planmaceutical Industries Limited, a company incorporated under the law of Israel, or any successor thereto (the "Company"), with the U.S. Securites and Exchange Commission, any national securities exchanges and the Company or advisable under Section 16(a) of the Securities Exchange Act of 193 and the rules and regulations promulgated thereunder, as amended from time (the "Exchange Act");
• (2) = seek or obtain, as the undersigned's behalf, information of transations in the Company's securities from any third-party, including brokers, employee benefit plan administrators and the undersigned hereby authorizes any such information to the undersigned and approves and ratifies any such release of information; and
• (3) a perform any and all other acts which attorney-in-fact is necessary or desirable for and on bethalf of the undersigned in connection with the foregoing.

The undersigned acknowledges that:

• (4) = this Pover of Attorney authorizes, but attorney-in-fact to act in his or her discetion on information provided to such attomer-in-fact without independent verification of such information;
• (5) = any documents prepared, executed, and or delivered by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney vill be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;
• (6) = nether the Company nor such attomes (1) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (1) any lability of the undersigned for any failure to comprenents or (ii) any obligation or liability of the undersigned in er Section 16(b) of the Exchange Act; and
• (7) = this Pover of Attorney does not relieve the responsibility for complance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 16 of the Exchange Act.

The undersigned hereby gives and grants the fill pover and authority to do and perform all and every act and thing whatsover requisite, necessary or appropriate to be done in and about the foregoing maters and purposes as the undersigned might or could do if present, beroly ratifying all that such atterin-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Power of Attorney.

This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to such attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 29th day of February, 2024.

By: /s/ David R. McAvoy Name: David McAvoy Title: EVP, Chief Legal Officer